The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting significant regulatory and commercial challenges for the medical device sector, the Unified Patent Court has issued a sales ban on Siemens Healthineers' MAMMOMAT B.brilliant system in Germany, France, and the Netherlands. The ruling follows a lawsuit filed by Hologic, which accused Siemens of infringing a patent covering technology designed to prevent image blurring during mammography. Siemens Healthineers has announced its intention to appeal the decision, which also dismissed its counterclaim seeking the revocation of the patent.
This legal dispute occurs amid intensifying competition in the digital medical imaging market, where Hologic serves as a primary rival to Siemens in 3D breast tomosynthesis technology. Per market data, the exclusion of Siemens from three major European markets could allow Hologic to expand its market share, particularly as the disputed patent (EP 2 352 431) is critical for diagnostic imaging quality. Legal experts note that the Unified Patent Court (UPC) rulings are increasingly demonstrating rapid, cross-border impacts on technical disputes within the European Union.
Regarding market performance, Siemens Healthineers (0PMJ.L) stood at 34.85 EUR (at close July 03, 2026) as investors weigh the potential impact of the sales halt. Market participants are now looking for further clarity on the appeal timeline and will be monitoring the upcoming speech by ECB President Lagarde later today for broader sentiment cues affecting the European healthcare and industrial sectors.